Stockscreener 앱 받기
37.04
0.07%
0.05
전일 마감가:
$36.99
열려 있는:
$37.5
하루 거래량:
655.22K
Relative Volume:
0.39
시가총액:
$6.80B
수익:
$520.18M
순이익/손실:
$-348.13M
주가수익비율:
-19.29
EPS:
-1.92
순현금흐름:
$-176.18M
1주 성능:
-1.71%
1개월 성능:
-4.99%
6개월 성능:
+1.72%
1년 성능:
-35.15%
1일 변동 폭
$36.81
$37.99
1주일 범위
$35.23
$38.22
52주 변동 폭
$27.34
$59.62
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
36.98 | 6.67B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.84 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.77 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.97 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
647.43 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.13 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $83.00 at Morgan Stanley - Defense World
Legend Biotech (NASDAQ:LEGN) Receives Outperform Rating from Royal Bank Of Canada - Defense World
Legend Biotech stock price target raised to $77 by RBC Capital - Investing.com South Africa
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth - Investing.com
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth By Investing.com - Investing.com South Africa
Legend Biotech Q2 2025 slides: CARVYKTI sales surge 136%, adjusted profit achieved - Investing.com
XTX Topco Ltd Takes $307,000 Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
Legend Biotech on Track for Record Losing Streak — Data Talk - Morningstar
Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings - Defense World
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential By Investing.com - Investing.com South Africa
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential - Investing.com India
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Barchart.com
Oracle and GameStop Headline Market Cap Stock Movers on Thursday By Investing.com - Investing.com South Africa
Eli Lilly, General Electric among Tuesday’s market cap stock movers By Investing.com - Investing.com India
Eli Lilly, General Electric among Tuesday’s market cap stock movers - Investing.com
CARVYKTI shows lasting impact in multiple myeloma treatment By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock - Investing.com India
BMO Capital reaffirms outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
BMO Capital reaffirms outperform rating on Legend Biotech stock - Investing.com India
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com India
RBC Capital maintains Legend Biotech at outperform with $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Legend Biotech at outperform with $78 target - Investing.com
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com
Legend Biotech stock holds $62 target, solid Carvykti sales growth - Investing.com India
Legend Biotech stock holds $62 target, solid Carvykti sales growth By Investing.com - Investing.com UK
Truist cuts Legend Biotech stock target to $71, maintains buy rating - Investing.com India
Raymond James maintains Legend Biotech Outperform rating - Investing.com
Raymond James maintains Legend Biotech Outperform rating By Investing.com - Investing.com UK
Earnings call transcript: Legend Biotech Q1 2025 sees strong CARVICTI sales boost - Investing.com India
Legend Biotech Q1 2025 slides: CARVYKTI sales surge 135% as path to profitability clarifies - Investing.com India
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights - GlobeNewswire Inc.
Stock Surge: Legend Biotech Corp ADR (LEGN) Closes at 31.37, Marking a -6.08 Increase/Decrease - DWinneX
What Makes Legend Biotech (LEGN) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet - Yahoo Finance
Top investors say Legend Biotech Corp ADR (LEGN) ticks everything they need - Sete News
LEGN stock rated a Buy by Redburn Atlantic - knoxdaily.com
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
자본화:
|
볼륨(24시간):